TC Biopharm plc is a clinical-stage immunotherapy company focused on the development and commercialization of personalized cancer vaccines. Utilizing an autologous dendritic cell platform, the company engineers patient-specific immunotherapies designed to boost antitumor immune response. Its lead program, TCB-202, is a follicular lymphoma vaccine in advanced clinical trials, while additional candidates are in development for head and neck and other solid tumors.
The company operates a central manufacturing facility in Herford, Germany, and maintains clinical development offices in Dublin, Ireland, with supporting activities in the United States. TC Biopharm’s vaccines are custom-manufactured to present tumor-associated antigens to patients’ immune systems, with the goal of achieving durable remission and improving survival outcomes. Through partnerships with leading cancer centers and academic institutions, the firm has initiated multiple Phase II and bridge trials across Europe, the U.K. and North America.
Founded in 2011 and headquartered in Dublin, TC Biopharm has evolved from a research collaboration into a fully integrated biopharmaceutical organization. Early research contributions emerged from collaborations with university immunology departments, and the company subsequently established its own GMP-compliant production lines. Over the past decade, TC Biopharm has expanded its pipeline and attracted grant funding and strategic research alliances to support its clinical development programs.
TC Biopharm is led by Chief Executive Officer John Finley, who brings over 25 years of leadership experience in biotechnology and oncology drug development. Chief Scientific Officer Emily Chen oversees the company’s R&D efforts, drawing on her expertise in cellular immunotherapy. Together with a management team composed of veterans from major biopharma firms, they aim to advance the company’s personalized vaccine platform toward regulatory approval and commercialization.
AI Generated. May Contain Errors.
